PACIFIC Pays Off Again For AZ With Imfinzi Lung Cancer OS Success

25 May 2018

Having already got off to a strong start on the US market on the back of stellar progression-free survival data, AstraZeneca’s immunotherapy Imfinzi has hit a second primary endpoint of the PACIFIC trial by improving overall survival in unresectable Stage III NSCLC patients, raising the bar even higher for future competition from rival PD-1/L1 inhibitors.

Cycling — Imfinzi stays ahead of the pack in earlier-stage NSCLC • Source: Shutterstock

Fresh data from the key PACIFIC trial showing that Imfinzi (durvalumab) significantly improves overall survival (OS) in patients with earlier stage non-small cell lung cancer (NSCLC) has placed AstraZeneca PLC further ahead of the chasing checkpoint inhibitor pack in this indication.

The company has announced that a planned interim analysis conducted by an independent data monitoring committee concluded that the Phase...